Adma Biologics Stock Investor Sentiment

ADMA Stock  USD 21.18  0.12  0.56%   
About 57% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
  

ADMA Biologics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at businesswire.com         
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law...
businesswire News
over two weeks ago at finance.yahoo.com         
CRISPR Therapeutics AG Reports Q3 Loss, Lags Revenue Estimates
Yahoo News
over two weeks ago at businesswire.com         
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc.
businesswire News
over two weeks ago at businesswire.com         
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc.
businesswire News
over two weeks ago at finance.yahoo.com         
Adma Biologics Soars 18.8 percent Is Further Upside Left in the Stock?
Yahoo News
over two weeks ago at zacks.com         
Adma Biologics Soars 18.8 percent Is Further Upside Left in the Stock?
zacks News
over two weeks ago at investors.com         
TG Therapeutics Crashes Reversing A Breakout On Its Mixed Third-Quarter Results
Investors Business Daily at Macroaxis
over two weeks ago at investors.com         
BioNTech Jumps On Surprise Profit, Wide Sales Beat But Lowers Outlook
Investors Business Daily at Macroaxis
over two weeks ago at talkmarkets.com         
Buckle Up And Use Volatility To Your Advantage
news
over three weeks ago at zerohedge.com         
Futures Rise Ahead Of Payrolls As Tech Stocks Rebound
news
over three weeks ago at investing.com         
Amazon and Atlassian lead afternoon market cap stock movers this Friday
Investing News at Macroaxis
over three weeks ago at seekingalpha.com         
ADMA Biologics stock jumps after naming auditor
seekingalpha News
over three weeks ago at investors.com         
ADMA Biologics, A Top 1 percent Stock, Skyrockets After Settling Its Accounting Debacle
Investors Business Daily at Macroaxis
over three weeks ago at investors.com         
Madrigal Catapults After Novos Wegovy Proves Its No Silver Bullet In MASH
Investors Business Daily at Macroaxis
over three weeks ago at zacks.com         
Wall Street Bulls Look Optimistic About Adma Biologics Should You Buy?
zacks News
Far too much social signal, news, headlines, and media speculation about ADMA Biologics that are available to investors today. That information is available publicly through ADMA media outlets and privately through word of mouth or via ADMA internal channels. However, regardless of the origin, that massive amount of ADMA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ADMA Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ADMA Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ADMA Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ADMA Biologics alpha.

ADMA Biologics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 24150 shares by Kestenberg-messina Kaitlin M. of ADMA Biologics at 16.8965 subject to Rule 16b-3
09/27/2024
2
Acquisition by Adam Grossman of 870950 shares of ADMA Biologics at 5.4 subject to Rule 16b-3
10/04/2024
3
Wall Street Bulls Look Optimistic About Adma Biologics Should You Buy
10/30/2024
4
ADMA Biologics Q3 2024 Earnings Preview
11/06/2024
5
Recent Price Trend in Adma Biologics is Your Friend, Heres Why
11/11/2024
6
The Schall Law Firm Invites Shareholders To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/13/2024
7
AWM Investment Company, Inc. Acquires New Stake in Burcon NutraScience Corp
11/15/2024
8
Wall Street Analysts See a 31.3 percent Upside in Adma Biologics Can the Stock Really Move This High
11/18/2024
9
ADMA Biologics shares retain Outperform rating on performance
11/19/2024
10
The Schall Law Firm Encourages Shareholders To Take Part In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
11/21/2024
11
Disposition of 48967 shares by Adam Grossman of ADMA Biologics at 21.1 subject to Rule 16b-3
11/22/2024

Complementary Tools for ADMA Stock analysis

When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital